Vitamin D and its analogs in chronic renal failure

Osteoporosis International

Volumn 7, Issue SUPPL. 3, 1997, Pages

  Slatopolsky, E ^a   Brown, A J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; PARATHYROID HORMONE; TOXIN; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; HUMAN; HYPERPHOSPHATEMIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR DENSITY; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; VITAMIN D METABOLISM;

ANIMALS; CALCITRIOL; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; PARATHYROID HORMONE; PHOSPHATES; RATS; RECEPTORS, CALCITRIOL; UREMIA; VITAMIN D;

EID: 0031467062     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03194373     Document Type: Article

References (74)

1. Martinez I, Saracho R, Montenegro J, Llach F. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996;11:22-8.
2. Malluche H, Werner E, Ritz E. Intestinal absorption of calcium and whole-body calcium retention in incipient and advanced renal failure. Miner Electrolyte Metab 1978;1:263-70.
3. 3 by calcium and phosphorus in the rat. Science 1975;190:578-80.
4. 3-1α-hydroxylase by phosphate depletion. J Biol Chem 1976;251: 3158-63.
5. Tanaka Y, DeLuca HF. The control of 25-dihydroxyvitamin D. metabolism by inorganic phosphorus. Arch Biochem Biophys 1973;154:566-74.
6. 3 and parathyroid hormone in children with moderate renal failure. J Clin Invest 1984;73:1580-9.
7. Garabedian M, Holick MF, DeLuca HF, Boyle IT. Control of 25-hydroxycholecalciferol metabolism by the parathyroid glands. Proc Natl Acad Sci 1972;69:1673-6.
8. 3. J Clin Invest 1972;51:2502-10.
9. Haussler MR, McCain TA. Basic and clinical concepts related to vitamin D metabolism and action. N Engl J Med 1977;297:974-9.
10. Eisman JA, Wark JD, Prince RL, Moseley JM. Modulation of plasma 1,25-hydroxyvitamin D in man by stimulation or suppression tests. Lance 1979;2:931-5.
11. Henry HL. Insulin permits parathyroid hormone stimulation of 1,25-dihydroxyvitamin D production in cultured kidney cells. Endocrinology 1981;108:733-5.
12. Henry HL. Regulation of the synthesis of 1,25-dihydroxyvitamin D and 24,25-dihydroxyvitamin D in kidney cell culture. In: Kumar R, editors. Vitmain D: basic and clinical aspects. Boston: Martinus Niijhoff, 1984:151-74.
13. Hsu C, Patel S. Uremic plasma contains factor inhibiting 1α-hydroxylase activity. J Am Soc Nephrol 1992;3:947-52.
14. 2-1α-hydroxylase in vivo. J Biol Chem 1974;249:7584-92.
15. Tanaka Y, Lorec RS, DeLuca HF. The role of 1,25-dihydroxy-vitamin D and parathyroid hormone in the regulation of chick renal 25-dihydroxyvitamin D-24-hydroxylase. Arch Biochem Biophys 1975;171:521-6.
16. Dusso A, Lopez-Hilker S, Finch J, Slatopolsky E. Metabolic clearance rate and production rate of calcitriol in uremia. Kidney Int 1989;35:860-4.
17. Hsu C, Patel S, Young EW, Simpson RV. Production and degradation of calcitriol in renal failure rats. Am J Physiol 1987;22:F1015-9.
18. 3 in the parathyroid glands of patients with renal failure. N Engl J Med 1987;315:1573-7.
19. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-43.
20. 3 receptors in experimental uremia. Kidney Int 1987;32:3350-3.
21. 3 receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int 1989;35:19-23.
22. 9k in uraemic rats. Eur J Clin Invest 1991;21:521-6.
23. 3 and 22-oxacalcitrol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int 1996;50:34-9.
24. Shvil Y, Naveh-Many T, Barach P, Silver J. Regulation of parathyroid cell gene expression in expeirmental uremia. J Am Soc Nephrol 1990;1:99-104.
25. Patel SR, Ke HQ, Vanholder R, Hsu CH. Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate. Kidney Int 1994;46:129-33.
26. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 1995;96:50-9.
27. Patel SR, Ke HW, VanHolder R, Koening R, Hsu C. inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 1995;96:50-9.
28. Silver J, Naveh-Many T. Regulation of parathryoid hormone synthesis and secretion. Semin Nephrol 1994;14:175-94.
29. 3. Proc Natl Acad Sci USA 1992;89:8097-101.
30. 3 and binds the vitamin D receptor. Mol Endocrinol 1996;10:206-15.
31. 3 in the regulation of vitamin D receptor expression by rat parathyroid glands. Endocrinology 1995;136:1419-25.
32. Brown AJ, Zhong M, Finch J, Ritter C, McCracken R, Morrissey J, Slatopolsky E. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996;270:F454-60.
33. Kifor O, Moore FD, Wang P, Goldstein M, Vasselev P, Kifor I, Hebert C, Brown EM. Reduced immunostaining for the extracellular Ca sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81:1598-606.
34. Brown EM, Wilson E, Eastman RC, Pallotta J, Marynick SP. Abnormal regulation of parathyroid hormone release by calcium in secondary hyperparathyroidism due to chronic renal failure. J Clin Endocrinol Metab 1982;54:172-9.
35. 3 pulse therapy. Miner Electrolyte Metab 1995;21:223-8.
36. Naveh-Many T, Rahamimov R, Livini N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats: the effect of calcium, phosphate, and vitamin D. J Clin Invest 1995;96:1786-93.
37. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996;97:2534-40.
38. 3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcif Tissue Int 1988;43:213-8.
39. Kremer R, Bolivar I, Goltzman D, Hendy GN. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bone parathyroid cells. Endocrinology 1989;125:935-41.
40. Kollenkirchen U, Fox J, Walters MR. Normocalcemia without hyperparathyroidism in vitamin D-deficient rats. J Bone Miner Res 1991;6:273-8.
41. Slatopolsky E, Weerts C, Theilan J, Horst R, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J. Clin Invest 1984;74:2136-43.
42. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989;321:274-9.
43. 3. J Clin Invest 1989;83:1349-55.
44. Dunlay R, Rodrigues M, Felsenfeld AJ, Llach F. Direct inhibitory effect of calcitriol on parathyroid function (sigmoidal curve) in dialysis patients. Kidney Int 1989;36:1039-98.
45. Cannella G, Bonucci E, Roalla D, Ballanti P, Moriero E, DeGrandi R, Augeri C, Claudiani F, DiMaio G. Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long term intravenous calcitriol. Kidney Int 1994;46:1124-32.
46. Bikle DD. Clinical counterpoint. Vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 1992;13:765-84.
47. Brown AJ, Dusso A, Slatopolsky E. Selective vitamin D analogs and their therapeutic applications. Semin Nephrol 1994;14:156-74.
48. Norman AW. The vitmain D endocrine system: manipulation of structure-function relationships to provide opportunities for development of new cancer chemopreventive and immunosuppressive agents. J Cell Biochem 1995;22:S218-25.
49. 3: preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro. Proc Natl Acad Sci USA 1987;84:2610-4.
50. Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vito. Biochem Pharmacol 1988;37:889-95.
51. Zhou JY, Norman AW, Lubbert M, Collins ED, Uskokovic MR, Koeffler HP. Novel vitamin D anlogs that modulate leukemia cell growth and differentiation with little effect on either intestinal calcium absorption or bone calcium mobilization. Blood 1989; 74:82-93.
52. 3 with an oxygen atom in their side chain. Biochem Int 1989;19:1143-9.
53. 3 analogues on the proliferation of differentiation of cultured human keratinocytes, calcium metabolism and differentiation of human HL-60 cells. J Nutr Biochem 1993;4:49-57.
54. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 1991;129:832-7.
55. 3, a potent angiogenesis inhibitor, on rat mammary tumors induced by 7,12-dimethylbenz[a]anthracene. Anticancer Drugs 1991;2:475-80.
56. Colston KW, Chander SK, MacKay AG, Coombes RC. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992;44:693-702.
57. 3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology 1989; 124:2645-7.
58. Brown AJ, Ritter CS, Finch JL, Morrissey J, Martin KJ, Murayama E, et al. The noncalecmic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989;84:728-32.
59. 2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am J Kidney Dis 1995;26:852-60.
60. 3. J Nutr Sci Vitaminol 1989;35:529-33.
61. Dusso A, Gunawardhana S, Negrea L, Finch JL, Lopez-Hilker S, Mori T, et al. On the mechanisms for the selective action of vitamin D analogs. Endocrinology 1991;128:1687-92.
62. 3, in rats. J Biochem 1994;115:373-80.
63. Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E. The mechanism for the disparate actions of calcitirol and 22-oxacalcitriol in the intestine. Endocrinology 1993;133:2719-24.
64. Bouillon R, Allewaert K, Xiang DZ, Tan BK, van Baelen H. Vitamin D analogs with low affinity for the vitamin D binding protein: enhanced in vitro and decreased in vivo activity. J Bone Miner Res 1991;6:1051-7.
65. Tramoto T, Endo K, Ikeda K, Kubodera N, Kinoshita M, Yamanaka M, Ogata E. Binding of vitamin D in low-density-lipoprotein (LDL) and LDL receptor-mediated pathway into cells. Biochem Biophys Res Commun 1995;215:199-204.
66. 3 for 1,25-dihydroxyvitamin D receptor and its effects on the synthesis of osteocalcin in human osteosarcoma cells. Biochem Biophys Res Commun 1990;169: 629-35.
67. 3 on human osteoblast-like cells in vitro. J Bone Miner Res 1989;4:S334.
68. 3 on alkaline phosphatase activity, osteocalcin and DNA synthesis by human osteoblastic cells in culture. Bone 1990;11:171-9.
69. 3 by normal human peripheral monocytes. Endocrinology 1993;133:1158-64.
70. 3 analog structure-function assessment of the rapid stimulation of intestinal calcium absorption (transcaltachia). J Bone Miner Res 1992;7:457-63.
71. 3. Mol Endocrinol 1995;9:1814-24.
72. 3. J Bone Miner Res 1992;7:835-9.
73. Dusso AS, Negrea L, Finch J, Kaminmura S, Lopez-Hilker S, Mori T, et al. The effect of 22-oxacalcitriol on serum calcitriol. Endocrinology 1992;130:3129-34.
74. Brown AJ, Slatopolsky E. Mechanisms for the selective actions of vitamin D analogs in vitamin D. In: Feldman D, editor. Vitimin D 1997;995-1009 San Diego: Academic Press (in press).